Posts tagged as: kevetrin back to homepage
 |
Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug(0) Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug. The trials are slated to be held at Harvard’s Dana-Farber Cancer Institute. Read More |
 |
Jim Boeheim and Cellceutix Team to Fight Cancer(0) Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing a novel drug to treat cancers and cancers which have proven resistant to today’s cancer therapies (drug-resistant cancers),is pleased to announce that Syracuse University’s legendary men’s basketball coach Jim Boeheim has joined Cellceutix as an advisor to the Company. Read More |
|
Cellceutix to Meet with FDA on New Psoriasis Drug(0) This one day might be the story called “The Little Biotech That Could”. Cellceutix Corp. (OTCBB: CTIX) has a pipeline of eight drugs with three that have already begun clinical trials (one for cancer, one for psoriasis and one for autism). The flagship drug, Kevetrin™ is being developed as an anti-cancer drug with clinical trials slated to be hosted at the vaunted Dana-Farber Cancer Center. Read More |
|
Cellceutix Novel Anti-Cancer Compound Kevetrin Presented at AACR Annual Meeting(0) Company on Schedule for Filing Amended IND - Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing small molecule drugs to treat severe medical conditions, including drug-resistant cancers, is pleased to provide shareholders an update on developments with its novel anti-cancer compound Kevetrin™. Read More |
 |
Cellceutix Pens Agreement for Cancer Drug with Beth Israel Deaconess(0) Cellceutix Corporation (OTCBB:CTIX) continues to align itself with the biggest names in oncology research in the world. This truly sets the company apart from most of it developmental peers, regardless of exchange-listing or size. The company has released news recently about FDA document submissions seeking guidance on 505(b)(2) clearance for its psoriasis drug (which has provider stellar pre-clinical data) in addition to the clinical trials for its flagship cancer drug, Kevetrin™, which should be starting at Dana-Farber in the coming months. Read More |
350.png&w=160&h=120&zc=1&q=100) |
Cellceutix Files Pre-IND Documentation with FDA for New Psoriasis Drug(0) Company Gets Started on Next Drug in Their Pipeline Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that it has filed a pre-IND submission with the U.S. Food and Drug Administration (FDA) on Prurisol™ (also termed “KM-133″), the Company’s drug in development as a novel treatment for psoriasis. Read More |
|
Cellceutix Featured on Front Page of Boston Business Journal(0) Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to announce that it was featured Friday, January 20th on the front page of the Boston Business Journal print edition. Owned by American City Business Journals, the Boston Business Journal is available in both print and online versions and reaches hundreds of thousands of subscribers each month. Read More |
|
Another Cancer Research Breakthrough for Cellceutix(0) Cellceutix Corporation (OTCBB:CTIX) has regularly reported significant breakthroughs in cancer research through studies of Kevetrin, the company’s novel cancer drug in development. Amazing data has been collected by Cellceutix researchers testing Kevetrin against many cancer lines, including head & neck, prostate, lung, colon, pancreatic and leukemia. Defining the Method of Action (MOA), first the p53 connection was discovered (potentially the “Holy Grail” for anticancer drugs), then the impact Kevetrin seems to have on the retinoblastoma protein. Read More |
 |
Cellceutix Plans Clinical Trials for Psoriasis and Cancer Drugs in 2012(0) Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to provide corporate updates on Kevetrin™, its novel drug in development for drug-resistant cancers, and KM-133, its compound being developed as a revolutionary psoriasis indication. Read More |
 |
BioTuesdays Says Cellceutix Better than Competition(0) Popular biotechnology website BioTuesdays.com published an article this morning on Cellceutix Corporation (OTCBB: CTIX) discussing the recent developments and significant potential of Cellceutix as a result of its cancer drug, Kevetrin, and other drugs in its pipeline. The article, titled “Cellceutix’s potential breakthrough in cancer research,” spends time noting the “Holy Grail” p53 connection Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
